Renowned oncologists discuss the case of a 75-year-old man with advanced renal cell carcinoma, providing insights into evaluation and frontline therapy choices.
OncLive’s April Roundup of Key FDA Decisions in Oncology
FDA Approval Insights: Ponatinib in Ph+ ALL
Retrospective Data Show Metastasectomy Plus Nephrectomy Improves Survival in Non–ccRCC
CRC Experts Highlight AE Management and Prevention Strategies for TAS-102/Bevacizumab, Regorafenib, and Fruquintinib
The Surprising Connection Between Male Infertility and Family Cancer Risk
FDA Accepts BLA for Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors
Dr Liu Previews ASCO 2024 Lung Cancer Data
Dr Rajkumar Previews ASCO 2024 Data in Multiple Myeloma
Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer
Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer